Suppr超能文献

糖尿病与心血管疾病:不止于血糖。

Cardiovascular disease in diabetes, beyond glucose.

机构信息

Divisions of Endocrinology, Metabolism and Diabetes, and Cardiology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA.

Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, and Department of Laboratory Medicine and Pathology, University of Washington Medicine Diabetes Institute, University of Washington, Seattle, WA, USA.

出版信息

Cell Metab. 2021 Aug 3;33(8):1519-1545. doi: 10.1016/j.cmet.2021.07.001. Epub 2021 Jul 21.

Abstract

Despite the decades-old knowledge that diabetes mellitus is a major risk factor for cardiovascular disease, the reasons for this association are only partially understood. While this association is true for both type 1 and type 2 diabetes, different pathophysiological processes may be responsible. Lipids and other risk factors are indeed important, whereas the role of glucose is less clear. This lack of clarity stems from clinical trials that do not unambiguously show that intensive glycemic control reduces cardiovascular events. Animal models have provided mechanisms that link diabetes to increased atherosclerosis, and evidence consistent with the importance of factors beyond hyperglycemia has emerged. We review clinical, pathological, and animal studies exploring the pathogenesis of atherosclerosis in humans living with diabetes and in mouse models of diabetes. An increased effort to identify risk factors beyond glucose is now needed to prevent the increased cardiovascular disease risk associated with diabetes.

摘要

尽管人们早在几十年前就已经认识到糖尿病是心血管疾病的一个主要危险因素,但这种关联的原因仍不完全清楚。虽然这种关联对 1 型和 2 型糖尿病都适用,但可能有不同的病理生理过程在起作用。脂质和其他危险因素确实很重要,而葡萄糖的作用则不那么明确。这种不明确性源于临床试验并未明确表明强化血糖控制可减少心血管事件。动物模型提供了将糖尿病与动脉粥样硬化增加联系起来的机制,并且出现了与高血糖以外的因素的重要性一致的证据。我们回顾了探索糖尿病患者和糖尿病小鼠模型中动脉粥样硬化发病机制的临床、病理和动物研究。现在需要加大努力来识别除葡萄糖以外的危险因素,以预防与糖尿病相关的心血管疾病风险增加。

相似文献

1
Cardiovascular disease in diabetes, beyond glucose.
Cell Metab. 2021 Aug 3;33(8):1519-1545. doi: 10.1016/j.cmet.2021.07.001. Epub 2021 Jul 21.
2
Glycemic control and cardiovascular disease: what's a doctor to do?
Curr Diab Rep. 2012 Jun;12(3):255-64. doi: 10.1007/s11892-012-0268-5.
3
Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials.
Ann N Y Acad Sci. 2013 Apr;1281(1):36-50. doi: 10.1111/nyas.12044. Epub 2013 Feb 6.
4
[Is an intensive glycaemic control beneficial in diabetes type 2?].
Dtsch Med Wochenschr. 2011 Sep;136(39):1940. doi: 10.1055/s-0031-1286394. Epub 2011 Sep 22.
6
Multifactorial aspects of the treatment of the type II diabetic patient.
Metabolism. 1997 Dec;46(12 Suppl 1):1-4. doi: 10.1016/s0026-0495(97)90308-5.
7
Cardiovascular disease and type 2 diabetes mellitus: regulating glucose and regulating drugs.
Curr Cardiol Rep. 2009 Jul;11(4):258-63. doi: 10.1007/s11886-009-0038-4.
8
Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
Cochrane Database Syst Rev. 2013 Nov 11(11):CD008143. doi: 10.1002/14651858.CD008143.pub3.
9
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
Am J Med. 2017 Jun;130(6S):S4-S17. doi: 10.1016/j.amjmed.2017.04.004.
10
Postprandial hyperglycemia as an etiological factor in vascular failure.
Cardiovasc Diabetol. 2009 Apr 29;8:23. doi: 10.1186/1475-2840-8-23.

引用本文的文献

3
Statin utilization and its predictors for the primary prevention of cardiovascular disease among type 2 diabetic patients in a resource-limited setting.
Front Endocrinol (Lausanne). 2025 Jul 4;16:1472300. doi: 10.3389/fendo.2025.1472300. eCollection 2025.
5
Prevalence and spatio-demographic variability of nutrition-related health issues in Kiribati.
Sci Rep. 2025 Jul 2;15(1):23390. doi: 10.1038/s41598-025-07152-w.
8
Time in target range for systolic blood pressure and stroke in people with and without diabetes: the Kailuan prospective cohort study.
Front Endocrinol (Lausanne). 2025 May 14;16:1537343. doi: 10.3389/fendo.2025.1537343. eCollection 2025.
10
Health Literacy and Cognitive Disorders in Diabetic Patients.
J Clin Med. 2025 Apr 25;14(9):2972. doi: 10.3390/jcm14092972.

本文引用的文献

2
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment.
Diabetes Care. 2021 May;44(5):1219-1227. doi: 10.2337/dc20-2842. Epub 2021 Mar 15.
3
Cardiovascular effects of omega-3 fatty acids: Hope or hype?
Atherosclerosis. 2021 Apr;322:15-23. doi: 10.1016/j.atherosclerosis.2021.02.014. Epub 2021 Feb 23.
5
Atherosclerosis Regression and Cholesterol Efflux in Hypertriglyceridemic Mice.
Circ Res. 2021 Mar 19;128(6):690-705. doi: 10.1161/CIRCRESAHA.120.317458. Epub 2021 Feb 3.
6
Pros and Cons of Aspirin for the Primary Prevention of Cardiovascular Events: A Secondary Study of Trial Sequential Analysis.
Front Pharmacol. 2021 Jan 14;11:592116. doi: 10.3389/fphar.2020.592116. eCollection 2020.
8
Specific NLRP3 Inhibition Protects Against Diabetes-Associated Atherosclerosis.
Diabetes. 2021 Mar;70(3):772-787. doi: 10.2337/db20-0357. Epub 2020 Dec 15.
9
10. Cardiovascular Disease and Risk Management: .
Diabetes Care. 2021 Jan;44(Suppl 1):S125-S150. doi: 10.2337/dc21-S010.
10
Association of apolipoprotein C3 with insulin resistance and coronary artery calcium in patients with type 1 diabetes.
J Clin Lipidol. 2021 Jan-Feb;15(1):235-242. doi: 10.1016/j.jacl.2020.10.006. Epub 2020 Oct 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验